1-Aminomethyl-5-methoxyindane

1-Aminomethyl-5-methoxyindane (AMMI), is a drug developed by a team led by David E. Nichols at Purdue University, which acts as a selective serotonin releasing agent (SSRA) and binds to the serotonin transporter with similar affinity to DFMDA.[1][2]

1-Aminomethyl-5-methoxyindane
Clinical data
Routes of
administration
Oral
ATC code
  • none
Legal status
Legal status
  • In general: uncontrolled
Identifiers
CAS Number
PubChem CID
ChemSpider
Chemical and physical data
FormulaC11H15NO
Molar mass177.247 g·mol−1
3D model (JSmol)
 NY (what is this?)  (verify)

See also

References

  1. Roman, D. L.; Saldaña, S. N.; Nichols, D. E.; Carroll, F. I.; Barker, E. L. (2004). "Distinct molecular recognition of psychostimulants by human and Drosophila serotonin transporters". Journal of Pharmacology and Experimental Therapeutics. 308 (2): 679–87. doi:10.1124/jpet.103.057836. PMID 14593087.
  2. Walline, C. C.; Nichols, D. E.; Carroll, F. I.; Barker, E. L. (2008). "Comparative molecular field analysis using selectivity fields reveals residues in the third transmembrane helix of the serotonin transporter associated with substrate and antagonist recognition". Journal of Pharmacology and Experimental Therapeutics. 325 (3): 791–800. doi:10.1124/jpet.108.136200. PMC 2637348. PMID 18354055.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.